Cyclosporine-treated kidney transplants from living-related donors--a single center trial.
Analysis of 369 CsA-treated recipients transplanted with living-related donor grafts was presented along with the results of a control group of 160 recipients treated with AZ. 1. The 5-year graft survival was 78.2% in the CsA group as opposed to 58.5% in the control group. However, serum creatinine levels in the CsA group were higher than those in the CT group. 2. DST was carried out in recipients showing response to MLR. The fact that no significant difference was found between the DST and non-DST groups despite the poor tissue matching, may favor the effect of DST in CsA-treated recipients. 3. The graft survival rate in patients with a transient positive crossmatch was lower than that obtained in patients with no history of a positive crossmatch. 4. Incidence of acute rejection was highest in T-cell antibody positive cases, while the incidence of chronic rejection was highest in cold B-cell positive cases. 5. The combined use of AZ and local graft irradiation successfully suppressed the formation of antibodies to blood group antigens. 6. Detailed analysis and follow-up studies will be necessary to establish the optimum regimen of CsA administration for the long-term maintenance of renal function in CsA-treated recipients.